The approval comes after the FDA granted Ryanodex priority review status in March 2014.
The singe-use vial allows healthcare professionals to prepare and deliver dantrolene sodium, the only antidote for malignant hyperthermia — a rare genetic condition — much more efficiently than other products currently on the market and can be administered in less than one minute by a single healthcare professional, according to Eagle.
More articles on accreditation:
Paper-based record keeping could affect patient safety, study finds
AAAHC celebrates 35 years
Emergency drill toolkit
